Median time on treatment for the whole group of proven and suspected EGFR mutant NSCLC was 4.4 months (range 0.2 to 101), with 7 (18%) who had been on afatinib for ≥18 months, 3 for ≥36 months and 2 still ongoing as of June 2023 (101 months each). This evidence concerns the gene EGFR and non-small cell lung carcinoma.